Jump to content
Wikipedia The Free Encyclopedia

DSP-6745

From Wikipedia, the free encyclopedia

Pharmaceutical compound
DSP-6745
Clinical data
Other namesDSP6745
Routes of
administration 		Oral [1]
Drug class Serotonin reuptake inhibitor; Serotonin 5-HT2A receptor antagonist; Serotonin 5-HT2C receptor antagonist; Serotonin 5-HT7 receptor antagonist
ATC code
  • None
Identifiers
  • 1-[5-[(2,5-difluorophenyl)methoxy]-1-(3,3-dimethylbutyl)pyrazol-3-yl]-N-methylmethanamine
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C18H25F2N3O
Molar mass 337.415g·mol−1
3D model (JSmol)
  • CC(C)(C)CCN1C(=CC(=N1)CNC)OCC2=C(C=CC(=C2)F)F
  • InChI=1S/C18H25F2N3O/c1-18(2,3)7-8-23-17(10-15(22-23)11-21-4)24-12-13-9-14(19)5-6-16(13)20/h5-6,9-10,21H,7-8,11-12H2,1-4H3
  • Key:CESJQKNECLKVHF-UHFFFAOYSA-N

DSP-6745 is a serotonergic agent which was under development for the treatment of psychotic disorders but was never marketed.[1] [2] [3] It is taken orally.[1]

The drug acts as a serotonin reuptake inhibitor (SRI) and as an antagonist of the serotonin 5-HT2A, 5-HT2C, and 5-HT7 receptors.[3] Its affinities (Ki) were 0.653nM for the serotonin transporter (SERT), 0.331nM for the serotonin 5-HT2A receptor, 1.34nM for the serotonin 5-HT2C receptor, and 31.7nM for the serotonin 5-HT7 receptor.[3] Conversely, its IC50 Tooltip half-maximal inhibitory concentration or Kb values were 0.753nM at the SERT, 0.566nM at the serotonin 5-HT2A receptor, 1.37nM at the serotonin 5-HT2C receptor, and 2.12nM at the serotonin 5-HT7 receptor.[3] It also shows lower affinity for a number of other receptors, such as the serotonin 5-HT2B receptor (Ki = 7.58nM).[3] DSP-6745 produces antidepressant-like, anxiolytic-like, antipsychotic-like, and pro-cognitive effects in animals.[3]

The chemical synthesis of DSP-6745 has been described.[3]

DSP-6745 was first described in the scientific literature by 2024.[3] It was under development by Sumitomo Dainippon Pharma or Sumitomo Pharma.[1] [2] The drug reached phase 1 clinical trials for psychotic disorders prior to the discontinuation of its development in November 2022.[1] [2]

See also

[edit ]

References

[edit ]
  1. 1 2 3 4 5 "DSP 6745". AdisInsight. 21 November 2022. Retrieved 5 June 2026.
  2. 1 2 3 "Delving into the Latest Updates on DSP-6745 with Synapse". Synapse. 16 May 2026. Retrieved 5 June 2026.
  3. 1 2 3 4 5 6 7 8 Kitaichi M, Kato T, Oki H, Tatara A, Kawada T, Miyazaki K, et al. (November 2024). "DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects". Psychopharmacology. 241 (11). Berl: 2223–2239. doi:10.1007/s00213-024-06629-2. PMID 38856765.

AltStyle によって変換されたページ (->オリジナル) /